Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 448

1.

Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43].

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2019 Sep 10:172656. doi: 10.1016/j.ejphar.2019.172656. [Epub ahead of print] No abstract available.

PMID:
31519354
2.

Probing the CB1 cannabinoid receptor binding pocket with AM6538, a high-affinity irreversible antagonist.

Laprairie RB, Vemuri K, Stahl EL, Korde A, Ho JH, Grim TW, Hua T, Wu Y, Stevens RC, Liu ZJ, Makriyannis A, Bohn LM.

Mol Pharmacol. 2019 Sep 12. pii: mol.119.116483. doi: 10.1124/mol.119.116483. [Epub ahead of print]

3.

In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids.

Sachdev S, Vemuri K, Banister SD, Longworth M, Kassiou M, Santiago M, Makriyannis A, Connor M.

Br J Pharmacol. 2019 Aug 14. doi: 10.1111/bph.14829. [Epub ahead of print]

PMID:
31412133
4.

The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats.

Ogden SB, Malamas MS, Makriyannis A, Eckel LA.

Br J Pharmacol. 2019 Jul 22. doi: 10.1111/bph.14797. [Epub ahead of print]

PMID:
31328790
5.

Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity.

Argueta DA, Perez PA, Makriyannis A, DiPatrizio NV.

Front Physiol. 2019 Jun 11;10:704. doi: 10.3389/fphys.2019.00704. eCollection 2019.

6.

The sesquiterpene beta-caryophyllene oxide attenuates ethanol drinking and place conditioning in mice.

Oppong-Damoah A, Blough BE, Makriyannis A, Murnane KS.

Heliyon. 2019 Jun 12;5(6):e01915. doi: 10.1016/j.heliyon.2019.e01915. eCollection 2019 Jun.

7.

Endocannabinoid Metabolome Characterization of Milk from Guatemalan Women Living in the Western Highlands.

Gaitán AV, Wood JT, Solomons NW, Donohue JA, Ji L, Liu Y, Nikas SP, Zhang F, Allen LH, Makriyannis A, Lammi-Keefe CJ.

Curr Dev Nutr. 2019 Mar 27;3(6):nzz018. doi: 10.1093/cdn/nzz018. eCollection 2019 Jun.

8.

Chronic low dose arsenic exposure preferentially perturbs mitotic phase of the cell cycle.

Ganapathy S, Liu J, Xiong R, Yu T, Makriyannis A, Chen C.

Genes Cancer. 2019 Feb;10(1-2):39-51. doi: 10.18632/genesandcancer.185.

9.

Biochemical and Proteomic Characterization of Recombinant Human α/β Hydrolase Domain 6.

Shields CM, Zvonok N, Zvonok A, Makriyannis A.

Sci Rep. 2019 Jan 29;9(1):890. doi: 10.1038/s41598-018-36633-4.

10.

Crystal Structure of the Human Cannabinoid Receptor CB2.

Li X, Hua T, Vemuri K, Ho JH, Wu Y, Wu L, Popov P, Benchama O, Zvonok N, Locke K, Qu L, Han GW, Iyer MR, Cinar R, Coffey NJ, Wang J, Wu M, Katritch V, Zhao S, Kunos G, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Cell. 2019 Jan 24;176(3):459-467.e13. doi: 10.1016/j.cell.2018.12.011. Epub 2019 Jan 10.

PMID:
30639103
11.

Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.

D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD.

Lancet Psychiatry. 2019 Jan;6(1):35-45. doi: 10.1016/S2215-0366(18)30427-9. Epub 2018 Dec 6.

PMID:
30528676
12.

Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG.

Mol Pharmacol. 2019 Feb;95(2):155-168. doi: 10.1124/mol.118.113233. Epub 2018 Nov 30.

PMID:
30504240
13.

Cannabinoid-induced lower lip retraction in rats.

Chopda GR, Nikas SP, Sharma R, Kulkarni S, Makriyannis A, Paronis CA.

Psychopharmacology (Berl). 2019 Apr;236(4):1199-1206. doi: 10.1007/s00213-018-5125-z. Epub 2018 Nov 20.

PMID:
30460515
14.

Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment.

Alapafuja SO, Malamas MS, Shukla V, Zvonok A, Miller S, Daily L, Rajarshi G, Miyabe CY, Chandrashekhar H, Wood J, Tyukhtenko S, Straiker A, Makriyannis A.

Bioorg Med Chem. 2019 Jan 1;27(1):55-64. doi: 10.1016/j.bmc.2018.11.003. Epub 2018 Nov 3.

PMID:
30446439
15.

Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins.

Szymanski D, Papanastasiou M, Pandarinathan L, Zvonok N, Janero DR, Pavlopoulos S, Vouros P, Makriyannis A.

J Med Chem. 2018 Dec 27;61(24):11199-11208. doi: 10.1021/acs.jmedchem.8b01302. Epub 2018 Dec 10.

PMID:
30444608
16.

Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward.

Sagheddu C, Scherma M, Congiu M, Fadda P, Carta G, Banni S, Wood JT, Makriyannis A, Malamas MS, Pistis M.

Neuropharmacology. 2019 Jan;144:327-336. doi: 10.1016/j.neuropharm.2018.11.013. Epub 2018 Nov 12.

PMID:
30439418
17.

Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Slivicki RA, Saberi SA, Iyer V, Vemuri VK, Makriyannis A, Hohmann AG.

J Pharmacol Exp Ther. 2018 Dec;367(3):551-563. doi: 10.1124/jpet.118.252288. Epub 2018 Oct 1.

PMID:
30275151
18.

Fluorescent probes for G-protein-coupled receptor drug discovery.

Iliopoulos-Tsoutsouvas C, Kulkarni RN, Makriyannis A, Nikas SP.

Expert Opin Drug Discov. 2018 Oct;13(10):933-947. doi: 10.1080/17460441.2018.1518975. Epub 2018 Sep 24. Review.

PMID:
30249143
19.

Endocannabinoid Metabolome Characterization of Transitional and Mature Human Milk.

Gaitán AV, Wood JT, Zhang F, Makriyannis A, Lammi-Keefe CJ.

Nutrients. 2018 Sep 12;10(9). pii: E1294. doi: 10.3390/nu10091294.

20.

( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.

Liu Y, Ji L, Eno M, Kudalkar S, Li AL, Schimpgen M, Benchama O, Morales P, Xu S, Hurst D, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis DP, Zhou H, Honrao C, Mackie K, Reggio P, Hohmann AG, Marnett LJ, Makriyannis A, Nikas SP.

J Med Chem. 2018 Oct 11;61(19):8639-8657. doi: 10.1021/acs.jmedchem.8b00611. Epub 2018 Sep 21.

PMID:
30196704
21.

Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.

Barutta F, Bellini S, Mastrocola R, Gambino R, Piscitelli F, di Marzo V, Corbetta B, Vemuri VK, Makriyannis A, Annaratone L, Bruno G, Gruden G.

Br J Pharmacol. 2018 Dec;175(23):4371-4385. doi: 10.1111/bph.14495. Epub 2018 Nov 6.

PMID:
30184259
22.

Oximes short-acting CB1 receptor agonists.

Malamas MS, Raghav JG, Ma X, Honrao C, Wood JT, Benchama O, Zhou H, Mallipeddi S, Makriyannis A.

Bioorg Med Chem. 2018 Oct 1;26(18):4963-4970. doi: 10.1016/j.bmc.2018.08.003. Epub 2018 Aug 2.

PMID:
30122284
23.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2018 Oct 5;836:34-43. doi: 10.1016/j.ejphar.2018.08.016. Epub 2018 Aug 17. Erratum in: Eur J Pharmacol. 2019 Sep 10;:172656.

PMID:
30121173
24.

Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats.

Sticht MA, Lau DJ, Keenan CM, Cavin JB, Morena M, Vemuri VK, Makriyannis A, Cravatt BF, Sharkey KA, Hill MN.

Br J Pharmacol. 2019 May;176(10):1524-1540. doi: 10.1111/bph.14453. Epub 2018 Aug 22.

PMID:
30051485
25.

Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats.

He XH, Jordan CJ, Vemuri K, Bi GH, Zhan J, Gardner EL, Makriyannis A, Wang YL, Xi ZX.

Acta Pharmacol Sin. 2019 Mar;40(3):365-373. doi: 10.1038/s41401-018-0059-x. Epub 2018 Jul 2.

PMID:
29967454
26.

Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure.

Miller S, Kulkarni S, Ciesielski A, Nikas SP, Mackie K, Makriyannis A, Straiker A.

Pharmaceuticals (Basel). 2018 May 22;11(2). pii: E50. doi: 10.3390/ph11020050.

27.

Hydrogen-Deuterium Exchange Mass Spectrometry to Study Protein Complexes.

Kochert BA, Iacob RE, Wales TE, Makriyannis A, Engen JR.

Methods Mol Biol. 2018;1764:153-171. doi: 10.1007/978-1-4939-7759-8_10.

PMID:
29605914
28.

A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells.

Yu T, Ganapathy S, Shen L, Peng B, Kim SH, Makriyannis A, Chen C.

Oncotarget. 2018 Jan 4;9(5):6308-6319. doi: 10.18632/oncotarget.23918. eCollection 2018 Jan 19.

29.

Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor.

Mallipeddi S, Zvonok N, Makriyannis A.

Sci Rep. 2018 Feb 13;8(1):2935. doi: 10.1038/s41598-018-19749-5.

30.

Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase.

Tyukhtenko S, Rajarshi G, Karageorgos I, Zvonok N, Gallagher ES, Huang H, Vemuri K, Hudgens JW, Ma X, Nasr ML, Pavlopoulos S, Makriyannis A.

Sci Rep. 2018 Jan 29;8(1):1719. doi: 10.1038/s41598-017-19135-7.

31.

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Paronis CA, Chopda GR, Vemuri K, Zakarian AS, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2018 Mar;364(3):485-493. doi: 10.1124/jpet.117.245647. Epub 2018 Jan 8.

32.

Secretion, isotopic labeling and deglycosylation of N-acylethanolamine acid amidase for biophysical studies.

Pavlopoulos S, Pelekoudas DN, Benchama O, Rawlins CM, Agar JN, West JM, Malamas M, Zvonok N, Makriyannis A.

Protein Expr Purif. 2018 May;145:108-117. doi: 10.1016/j.pep.2017.12.005. Epub 2017 Dec 15.

33.

Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.

Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, Sershen H, Suckow RF, Vinod KY.

Neuropharmacology. 2018 Mar 15;131:200-208. doi: 10.1016/j.neuropharm.2017.10.040. Epub 2017 Nov 3.

34.

Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages.

Ruiz de Azua I, Mancini G, Srivastava RK, Rey AA, Cardinal P, Tedesco L, Zingaretti CM, Sassmann A, Quarta C, Schwitter C, Conrad A, Wettschureck N, Vemuri VK, Makriyannis A, Hartwig J, Mendez-Lago M, Bindila L, Monory K, Giordano A, Cinti S, Marsicano G, Offermanns S, Nisoli E, Pagotto U, Cota D, Lutz B.

J Clin Invest. 2017 Nov 1;127(11):4148-4162. doi: 10.1172/JCI83626. Epub 2017 Oct 16.

35.

Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.

Leonard MZ, Alapafuja SO, Ji L, Shukla VG, Liu Y, Nikas SP, Makriyannis A, Bergman J, Kangas BD.

J Pharmacol Exp Ther. 2017 Dec;363(3):314-323. doi: 10.1124/jpet.117.244392. Epub 2017 Sep 25.

36.

The role of human monoacylglycerol lipase (hMAGL) binding pocket in breakup of unsaturated phospholipid membranes.

Karageorgos I, Silin VI, Zvonok N, Marino J, Janero DR, Makriyannis A.

Anal Biochem. 2017 Nov 1;536:90-95. doi: 10.1016/j.ab.2017.08.009. Epub 2017 Aug 17.

PMID:
28822686
37.

Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Farizatto KLG, McEwan SA, Naidoo V, Nikas SP, Shukla VG, Almeida MF, Byrd A, Romine H, Karanian DA, Makriyannis A, Bahr BA.

J Mol Neurosci. 2017 Sep;63(1):115-122. doi: 10.1007/s12031-017-0963-4. Epub 2017 Aug 12.

PMID:
28803438
38.

Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.

Janero DR, Korde A, Makriyannis A.

Methods Enzymol. 2017;593:217-235. doi: 10.1016/bs.mie.2017.06.022. Epub 2017 Jul 3.

PMID:
28750804
39.

CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.

Wills KL, DeVuono MV, Limebeer CL, Vemuri K, Makriyannis A, Parker LA.

Behav Neurosci. 2017 Aug;131(4):304-11. doi: 10.1037/bne0000201.

PMID:
28714716
40.

Crystal structures of agonist-bound human cannabinoid receptor CB1.

Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH, Han GW, Ding K, Li X, Liu H, Hanson MA, Zhao S, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Nature. 2017 Jul 27;547(7664):468-471. doi: 10.1038/nature23272. Epub 2017 Jul 5.

41.

C1'-Azacycloalkyl Hexahydrocannabinols.

Ho TC, Shimada N, Tius MA, Nikas SP, Zhang W, Makriyannis A.

J Org Chem. 2017 Aug 4;82(15):7839-7849. doi: 10.1021/acs.joc.7b00988. Epub 2017 Jul 17.

PMID:
28677397
42.

s signalling of the CB1 receptor and the influence of receptor number.

Finlay DB, Cawston EE, Grimsey NL, Hunter MR, Korde A, Vemuri VK, Makriyannis A, Glass M.

Br J Pharmacol. 2017 Aug;174(15):2545-2562. doi: 10.1111/bph.13866. Epub 2017 Jun 19.

43.

Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.

Ganapathy S, Peng B, Shen L, Yu T, Lafontant J, Li P, Xiong R, Makriyannis A, Chen C.

Oncotarget. 2017 May 9;8(19):30992-31002. doi: 10.18632/oncotarget.16047.

44.

Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.

Barutta F, Grimaldi S, Gambino R, Vemuri K, Makriyannis A, Annaratone L, di Marzo V, Bruno G, Gruden G.

Nephrol Dial Transplant. 2017 Oct 1;32(10):1655-1665. doi: 10.1093/ndt/gfx010.

PMID:
28387811
45.

Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis.

Mallipeddi S, Kreimer S, Zvonok N, Vemuri K, Karger BL, Ivanov AR, Makriyannis A.

J Proteome Res. 2017 Jul 7;16(7):2419-2428. doi: 10.1021/acs.jproteome.7b00023. Epub 2017 Jun 19.

PMID:
28374590
46.

Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.

Zhou H, Peng Y, Halikhedkar A, Fan P, Janero DR, Thakur GA, Mercier RW, Sun X, Ma X, Makriyannis A.

ACS Chem Neurosci. 2017 Jun 21;8(6):1338-1347. doi: 10.1021/acschemneuro.7b00003. Epub 2017 Mar 1.

PMID:
28220706
47.

Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

McLaughlin PJ, Jagielo-Miller JE, Plyler ES, Schutte KK, Vemuri VK, Makriyannis A.

Psychopharmacology (Berl). 2017 Mar;234(6):1029-1043. doi: 10.1007/s00213-017-4548-2. Epub 2017 Feb 1.

PMID:
28144708
48.

N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.

Alhouayek M, Bottemanne P, Makriyannis A, Muccioli GG.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 May;1862(5):474-484. doi: 10.1016/j.bbalip.2017.01.001. Epub 2017 Jan 6.

PMID:
28065729
49.

Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.

Dhopeshwarkar A, Murataeva N, Makriyannis A, Straiker A, Mackie K.

J Pharmacol Exp Ther. 2017 Feb;360(2):300-311. doi: 10.1124/jpet.116.236539. Epub 2016 Dec 7.

50.

Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Mallipeddi S, Janero DR, Zvonok N, Makriyannis A.

Biochem Pharmacol. 2017 Mar 15;128:1-11. doi: 10.1016/j.bcp.2016.11.014. Epub 2016 Nov 24. Review.

Supplemental Content

Loading ...
Support Center